Targeted antivascular therapy with the apolipoprotein(a) kringle V, rhLK8, inhibits the growth and metastasis of human prostate cancer in an orthotopic nude mouse model

Neoplasia

Volumn 14, Issue 4, 2012, Pages 335-343

  Lee, Ho Jeong ^a,b   Yu, Hyun Kyung ^a   Papadopoulos, John N ^c   Kim, Seung Wook ^c   He, Junqin ^c   Park, Yong Keun ^b   Yoon, Yeup ^a   Kim, Jang Seong ^a   Kim, Sun Jin ^c  

^a Mogam Biotechnology Research Institute   (South Korea)

^b Korea University   (South Korea)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; CD31 ANTIGEN; CYCLINE; PACLITAXEL; RECOMBINANT PROTEIN; RHLK8; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DIGITAL RADIOGRAPHY; DOSE RESPONSE; ENDOTHELIUM CELL; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; KRINGLE DOMAIN; LYMPH NODE METASTASIS; MALE; MICROVASCULATURE; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; TIBIA; TUMOR GROWTH; TUMOR VOLUME;

EID: 84860643468     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.12380     Document Type: Article

References (56)

1. DeMarzo AM, Nelson WG, Isaacs WB, and Epstein JI (2003). Pathological and molecular aspects of prostate cancer. Lancet 361, 955-964.
2. Roy-Burman P, Zheng J, and Miller GJ (1997). Molecular heterogeneity in prostate cancer: can TP53 mutation unravel tumorigenesis? Mol Med Today 3, 476-482.
3. Dai B, Kim O, Xie Y, Guo Z, Xu K, Wang B, Kong X, Melamed J, Chen H, Bieberich CJ, et al. (2006). Tyrosine kinase Etk/BMX is up-regulated in human prostate cancer and its overexpression induces prostate intraepithelial neoplasia in mouse. Cancer Res 66, 8058-8064.
4. Smith PC, Hobisch A, Lin DL, Culig Z, and Keller ET (2001). Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev 12, 33-40.
5. Folkman J (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med 285, 1182-1186.
6. Folkman J (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1, 27-31.
7. Carmeliet P and Jain RK (2000). Angiogenesis in cancer and other diseases. Nature 407, 249-257.
8. Folkman J (2007). Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6, 273-286.
9. Mauriz JL and Gonzalez-Gallego J (2008). Antiangiogenic drugs: current knowledge and new approaches to cancer therapy. J Pharm Sci 97, 4129-4154.
10. Patthy L, Trexler M, Vali Z, Banyai L, and Varadi A (1984). Kringles: modules specialized for protein binding. Homology of the gelatin-binding region of fibronectin with the kringle structures of proteases. FEBS Lett 171, 131-136.
11. Cao Y, Cao R, and Veitonmaki N (2002). Kringle structures and antiangiogenesis. Curr Med Chem Anticancer Agents 2, 667-681.
12. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, and Lawn RM (1987). cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 330, 132-137.
13. Guevara J Jr, Knapp RD, Honda S, Northup SR, and Morrisett JD (1992). A structural assessment of the apo[a] protein of human lipoprotein[a]. Proteins 12, 188-199.
14. Kraft HG, Lingenhel A, Pang RW, Delport R, Trommsdorff M, Vermaak H, Janus ED, and Utermann G (1996). Frequency distributions of apolipoprotein(a) kringle IV repeat alleles and their effects on lipoprotein(a) levels in Caucasian, Asian, and African populations: the distribution of null alleles is non-random. Eur J Hum Genet 4, 74-87.
15. Fless GM, ZumMallen ME, and Scanu AM (1986). Physicochemical properties of apolipoprotein(a) and lipoprotein(a-) derived from the dissociation of human plasma lipoprotein (a). J Biol Chem 261, 8712-8718.
16. Callow MJ and Rubin EM (1995). Site-specific mutagenesis demonstrates that cysteine 4326 of apolipoprotein B is required for covalent linkage with apolipoprotein (a) in vivo. J Biol Chem 270, 23914-23917.
17. Kim JS, Chang JH, Yu HK, Ahn JH, Yum JS, Lee SK, Jung KH, Park DH, Yoon Y, Byun SM, et al. (2003). Inhibition of angiogenesis and angiogenesisdependent tumor growth by the cryptic kringle fragments of human apolipoprotein(a). J Biol Chem 278, 29000-29008.
18. Ahn JH, Kim JS, Yu HK, Lee HJ, and Yoon Y (2004). A truncated kringle domain of human apolipoprotein(a) inhibits the activation of extracellular signal-regulated kinase 1 and 2 through a tyrosine phosphatase-dependent pathway. J Biol Chem 279, 21808-21814.
19. Kim JS, Yu HK, Ahn JH, Lee HJ, Hong SW, Jung KH, Chang SI, Hong YK, Joe YA, Byun SM, et al. (2004). Human apolipoprotein(a) kringle V inhibits angiogenesis in vitro and in vivo by interfering with the activation of focal adhesion kinases. Biochem Biophys Res Commun 313, 534-540.
20. Yu HK, Kim JS, Lee HJ, Ahn JH, Lee SK, Hong SW, and Yoon Y (2004). Suppression of colorectal cancer liver metastasis and extension of survival by expression of apolipoprotein(a) kringles. Cancer Res 64, 7092-7098.
21. Yu HK, Ahn JH, Lee HJ, Lee SK, Hong SW, Yoon Y, and Kim JS (2005). Expression of human apolipoprotein(a) kringles in colon cancer cells suppresses angiogenesis-dependent tumor growth and peritoneal dissemination. J Gene Med 7, 39-49.
22. Lee K, Yun ST, Kim YG, Yoon Y, and Jo EC (2006). Adeno-associated virusmediated expression of apolipoprotein (a) kringles suppresses hepatocellular carcinoma growth in mice. Hepatology 43, 1063-1073.
23. Fidler IJ, Kim SJ, and Langley RR (2007). The role of the organ microenvironment in the biology and therapy of cancer metastasis. J Cell Biochem 101, 927-936.
24. McCabe NP, Kerr BA, Madajka M, Vasanji A, and Byzova TV (2011). Augmented osteolysis in SPARC-deficient mice with bone-residing prostate cancer. Neoplasia 13, 31-39.
25. Zhang J, Sud S, Mizutani K, Gyetko MR, and Pienta KJ (2011). Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model. Neoplasia 13, 23-30.
26. Wittig-Blaich SM, Kacprzyk LA, Eismann T, Bewerunge-Hudler M, Kruse P, Winkler E, Strauss WS, Hibst R, Steiner R, Schrader M, et al. (2011). Matrixdependent regulation of AKT in Hepsin-overexpressing PC3 prostate cancer cells. Neoplasia 13, 579-589.
27. Lee TH, Kim MD, Shin SY, Lim HK, and Seo JH (2006). Disruption of hexokinase II (HXK2) partly relieves glucose repression to enhance production of human kringle fragment in gratuitous recombinant Saccharomyces cerevisiae. J Biotechnol 126, 562-567.
28. Kang KY, Park JH, Lim IH, Kim SG, Park SH, Kim WK, Hong JW, You HK, Jung KH, and Kim CW (2006). Crystallization of antiangiogenic Kringle V derived from human apolipoprotein A: crystallization applied to purification and formulation. Biosci Biotechnol Biochem 70, 916-925.
29. Yazici S, Kim SJ, Busby JE, He J, Thaker P, Yokoi K, Fan D, and Fidler IJ (2005). Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice. Prostate 65, 203-215.
30. Kim SJ, Uehara H, Karashima T, Shepherd DL, Killion JJ, and Fidler IJ (2003). Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res 9, 1200-1210.
31. Uehara H, Kim SJ, Karashima T, Shepherd DL, Fan D, Tsan R, Killion JJ, Logothetis C, Mathew P, and Fidler IJ (2003). Effects of blocking plateletderived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 95, 458-470.
32. Mori S, Sawai T, Teshima T, and Kyogoku M (1988). A new decalcifying technique for immunohistochemical studies of calcified tissue, especially applicable to cell surface marker demonstration. J Histochem Cytochem 36, 111-114.
33. Kim SJ, Uehara H, Yazici S, Langley RR, He J, Tsan R, Fan D, Killion JJ, and Fidler IJ (2004). Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice. Cancer Res 64, 4201-4208.
34. Baish JW and Jain RK (2000). Fractals and cancer. Cancer Res 60, 3683-3688.
35. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, and Augustin HG (2000).Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 60, 1388-1393.
36. Weidner N, Carroll PR, Flax J, Blumenfeld W, and Folkman J (1993). Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143, 401-409.
37. Borre M, Offersen BV, Nerstrom B, and Overgaard J (1998). Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 78, 940-944.
38. Bono AV, Celato N, Cova V, Salvadore M, Chinetti S, and Novario R (2002). Microvessel density in prostate carcinoma. Prostate Cancer Prostatic Dis 5, 123-127.
39. Aragon-Ching JB and Dahut WL (2008). The role of angiogenesis inhibitors in prostate cancer. Cancer J 14, 20-25.
40. Gerber HP and Ferrara N (2005). Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65, 671-680.
41. Canu B, Fioravanti A, Orlandi P, Di Desidero T, Ali G, Fontanini G, Di Paolo A, Del Tacca M, Danesi R, and Bocci G (2011). Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. Neoplasia 13, 217-229.
42. Jain RK (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62.
43. Ma J and Waxman DJ (2008). Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther 7, 3670-3684.
44. Huang G and Chen L (2008). Tumor vasculature and microenvironment normalization: a possible mechanism of antiangiogenesis therapy. Cancer Biother Radiopharm 23, 661-667.
45. Perri SR, Nalbantoglu J, Annabi B, Koty Z, Lejeune L, Francois M, Di Falco MR, Beliveau R, and Galipeau J (2005). Plasminogen kringle 5-engineered glioma cells block migration of tumor-associated macrophages and suppress tumor vascularization and progression. Cancer Res 65, 8359-8365.
46. Yang X, Cheng R, Li C, Cai W, Ma JX, Liu Q, Yang Z, Song Z, Liu Z, and Gao G (2006). Kringle 5 of human plasminogen suppresses hepatocellular carcinoma growth both in grafted and xenografted mice by anti-angiogenic activity. Cancer Biol Ther 5, 399-405.
47. Perri SR, Martineau D, Francois M, Lejeune L, Bisson L, Durocher Y, and Galipeau J (2007). Plasminogen Kringle 5 blocks tumor progression by antiangiogenic and proinflammatory pathways. Mol Cancer Ther 6, 441-449.
48. Jin GH, Ma DY, Wu N, Marikar FM, Jin SZ, Jiang WW, Liu Y, and Hua ZC (2007). Combination of human plasminogen kringle 5 with ionizing radiation significantly enhances the efficacy of antitumor effect. Int J Cancer 121, 2539-2546.
49. Fan JK, Xiao T, Gu JF, Wei N, He LF, Ding M, and Liu XY (2008). Increased suppression of oncolytic adenovirus carrying mutant k5 on colorectal tumor. Biochem Biophys Res Commun 374, 198-203.
50. Li Y, Han W, Zhang Y, Yuan L, Shi X, Yu Y, and Wang J (2008). Intramuscular electroporation of a plasmid encoding human plasminogen kringle 5 induces growth inhibition of Lewis lung carcinoma in mice. Cancer Biother Radiopharm 23, 332-341.
51. Cao Y, Chen A, An SS, Ji RW, Davidson D, and Llinas M (1997). Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem 272, 22924-22928.
52. Ji WR, Barrientos LG, Llinas M, Gray H, Villarreal X, DeFord ME, Castellino FJ, Kramer RA, and Trail PA (1998). Selective inhibition by kringle 5 of human plasminogen on endothelial cell migration, an important process in angiogenesis. Biochem Biophys Res Commun 247, 414-419.
53. Lu H, Dhanabal M, Volk R, Waterman MJ, Ramchandran R, Knebelmann B, Segal M, and Sukhatme VP (1999). Kringle 5 causes cell cycle arrest and apoptosis of endothelial cells. Biochem Biophys Res Commun 258, 668-673.
54. Nguyen TM, Subramanian IV, Kelekar A, and Ramakrishnan S (2007). Kringle 5 of human plasminogen, an angiogenesis inhibitor, induces both autophagy and apoptotic death in endothelial cells. Blood 109, 4793-4802.
55. Davidson DJ, Haskell C, Majest S, Kherzai A, Egan DA, Walter KA, Schneider A, Gubbins EF, Solomon L, Chen Z, et al. (2005). Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucoseregulated protein 78. Cancer Res 65, 4663-4672.
56. Gonzalez-Gronow M, Kaczowka SJ, Payne S, Wang F, Gawdi G, and Pizzo SV (2007). Plasminogen structural domains exhibit different functions when associated with cell surface GRP78 or the voltage-dependent anion channel. J Biol Chem 282, 32811-32820.